
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has reported significant year-over-year (Y/Y) growth in transplant volumes, particularly with DCD (donation after circulatory death) organs, showcasing a 15% increase in DCD hearts and a remarkable 44% increase in DCD livers. Although overall quarterly transplant volume trends have shown mixed results, the increase in the DCD market has contributed to a 7% growth in the combined heart, liver, and lung transplant market quarter-to-date (QTD). The company anticipates potential upside drivers from new product launches and faster adoption rates in lung transplants, which together may support stronger revenue growth, with expectations for 4Q24 revenue exceeding $120 million, potentially aligning with consensus projections for 1Q25 and 2025.
Bears say
TransMedics Group has experienced a notable decline in donor brain-dead (DBD) organ transplants, with DBD livers and hearts showing decreases of 6% year-over-year, contributing to a broader trend of declining volumes in DBD organs. Despite a slight growth in donor circulatory-dead (DCD) organs, the overall transplant market remains volatile, posing risks to TransMedics' market position, particularly concerning increasing competition and potential share loss. Additionally, while revenue estimates for 2026 have been marginally raised, the decline in group multiples from 7.2x to 6.8x indicates a weakening investor sentiment towards the company's growth potential amidst ongoing challenges.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares